Viltepso
(Viltolarsen)Phase 3RNA therapy
Viltepso is a rna therapy that works as a Exon-Skipping Antisense Oligonucleotide.[2] It is being investigated across 1 indication, with its most advanced program in Phase 3.[1]
Viltepso is one of 24 aso programs targeting Duchenne Muscular Dystrophy. It is currently in Phase 3.
1
Indications
5
Total Trials
2
Active Trials
23
Competitors
3
FDA Applications
NDA/BLA/ANDA regulatory filings
2
Patents
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
40 competitors in Duchenne Muscular Dystrophy
#DrugCompanyPhaseTrials
1Isordil
AstraZenecaApproved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Coreg
Akero TherapeuticsApproved
Rapamune
PPrism Pharmaceuticals
Approved
Garamycin
SSchering-Plough
Approved
Advil
KKenvue Brands
Approved
Rifadin
SanofiPhase 3
Duvyzat
ItalfarmacoPhase 3
Vyondys 53
Sarepta TherapeuticsApproved
Agamree
CCatalyst Pharmaceuticals, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Duchenne Muscular Dystrophy3 trials
Safety and Efficacy1 trial
Regulatory
FDA Approval Timeline[4]
Aug 12, 2020
VILTEPSO
NDA NDA212154
Aug 12, 2020
VILTEPSO
NDA NDA212154
Mar 11, 2021
VILTEPSO
NDA NDA212154
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Viltolarsen. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Exon-Skipping Antisense Oligonucleotide[2]
- Modality
- RNA therapy[2]
- Highest Phase
- Phase 3[1]
- Company
- NNippon Shinyaku Co., Ltd.